The H1-pAIM2/pCAIX vaccine activated CAIX-specific CD8+ T cell proliferation and a CTL response, stimulated multifunctional CD8+ T cells to produce TNF-α, IL-2, and IFN-γ, and significantly inhibited tumor growth [55]. This evidence concerns the gene CD8A and neoplasm.